Clinical Oncology News - Pro/Con: Money for Drugs

Clinical Oncology News - Pro/Con: Money for Drugs

abstract: Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?

Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?

Conclusion
The negative trough in the lifetime net income of a cooperative group trial occurs because follow-up costs are typically not funded or are underfunded. CTDs accrue more patients in new trials to offset that deficit. The CTD uses revenue from accrual to existing trials to cross-subsidize past trials in follow-up. As the number of patients on follow-up increases, the fiscal deficit grows larger each year, perpetuating the cycle. 

Australia: media - Charities push for overhaul of cancer funding 03/02/2012

ASHLEY HALL: "Cancer charities are calling for a massive overhaul of the $300 million fundraising and research sector.

They're becoming concerned about what they say is duplication and waste within the cancer research field.

The head of the Cancer Council of Australia says the attention paid to breast, cervix and ovarian cancer comes at the expense of other high mortality cancers including lung and pancreatic cancer....."

Finding philanthropy: Like it? Pay for it : Nature News & Comment ('crowd funding')

The hard sell

Another objection to crowd-funding may be harder to shake. To sell a project, researchers need an attention-grabbing story (see ‘How to woo the crowd’). That is easy to construct if your subject of study is, say, saving pandas or curing cancer. It is less so for researchers working on polymers. So will crowd-funding prove profitable only for 'sexy' science?

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices -- American Journal of Public Health selected articles

Note: this journal is by subscription ($$$)

AJPH First Look, published online ahead of print Jan 13, 2011

April 2011, Vol 101, No. 4 | American Journal of Public Health 602-609
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2010.300027

GOVERNMENT, POLITICS, AND LAW

Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis of Disclosure Practices
Sheila M. Rothman, PhD, Victoria H. Raveis, PhD, Anne Friedman, BA and David J. Rothman, PhD
Sheila M. Rothman is with the Division of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, NY, and the Center for the Study of Society and Medicine,

College of Physicians and Surgeons, Columbia University. Victoria H. Raveis is with the Psychosocial Unit on Health, Ageing, and Community, New York University College of Dentistry, New

York. At the time of the study Anne Friedman was with the Center on Medicine as a Profession, College of Physicians and Surgeons, Columbia University. David J. Rothman is with the College
of Physicians and Surgeons, Columbia University.
Correspondence: Correspondence should be sent to Sheila M. Rothman, Center for the Study of Society and Medicine, College of Physicians and Surgeons, Columbia University,

630 West 168th St, PH 15-25, New York, NY 10032 (e-mail: smr4@columbia.edu). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" button.
Health advocacy organizations (HAOs) are influential stakeholders in health policy. Although their advocacy tends to closely correspond with the pharmaceutical industry's
marketing aims, the financial relationships between HAOs and the pharmaceutical industry have rarely been analyzed.
We used Eli Lilly and Company's grant registry to examine its grant-giving policies. We also examined HAO Web sites to determine their grant-disclosure patterns.

Only 25% of HAOs that received Lilly grants acknowledged Lilly's contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor.

No HAO disclosed the exact amount of a Lilly grant.
As highly trusted organizations, HAOs should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators,

and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.




This article has been cited by other articles:

				M. Weinberg Patient Advocacy Organizations and Corporate Relationships Am J Public Health, April 1, 2011; 101(4): 582 - 583. [Full Text] [PDF]

eLetters:

Read all eLetters

Health Advocacy Organizations: Transparency is important and so is evidence

Frances M Visco

AJPH Online, 17 Jan 2011 [Full text]

Patient Advocacy Organizations are Committed to Transparency

Myrl Weinberg

AJPH Online, 20 Jan 2011 [Full text]

Re: Health Advocacy Organizations and the Pharmaceutical Industry: An Analysis

Jack Harris, et al.

AJPH Online, 24 Jan 2011 [Full text]

abstract: Patient Advocacy Organizations and Corporate Relationships -- Weinberg 101 (4): 582 -- American Journal of Public Health

April 2011, Vol 101, No. 4 | American Journal of Public Health 582-583
© 2011 American Public Health Association
DOI: 10.2105/AJPH.2011.300087

LETTERS

Patient Advocacy Organizations and Corporate Relationships
Myrl Weinberg, MA
Myrl Weinberg is president of the National Health Council, Washington, DC.
Correspondence: Correspondence should be sent to Myrl Weinberg, National Health Council, 1730 M Street, NW, Suite 500, Washington, DC 20036-4561 (e-mail: mweinberg@nhcouncil.org). Reprints can be ordered at http://www.ajph.org by clicking the "Reprints/Eprints" link.

	Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Since its creation in 1920, the National Health Council (NHC) has been dedicated to the values of integrity, transparency, and honesty. It is crucial that the patients we represent, the public, and the policy makers receive accurate information about how patient advocacy organizations conduct their relationships with corporate America.
The NHC agrees with Rothman et al. about the need for transparency.¹ For this reason, any patient advocacy organization that wishes to join or retain its membership in the NHC must disclose funding received from corporations and present the information in an easily accessible manner within 6 months of the close . . . [Full Text]

Kuwaiti patients, Canadian care: Hospital executives seek revenue in foreign lands - The Globe and Mail

Medical News: Anesthesia Given by Nurses Found Safe - in Anesthesiology, Anesthesiology from MedPage Today

The analysis -- funded by the American Association of Nurse Anesthetists -- looked at what happened after Medicare allowed opting out in 2001.

The study was financed by the American Association of Nurse Anesthetists.
The authors did not report any potential conflicts but declared themselves to be "wholly responsible for the data, analyses, and conclusions."

CDC to Fund Molecular Genetic Test Pilot for Clinics, Labs | GenomeWeb

$1.25m boost for cancer fight (ovarian) Melbourne, Australia news article

Co-operation between patient organisations and the drug industry in Finland